Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing. [electronic resource]
Producer: 20150119Description: 357-62 p. digitalISSN:- 1876-4479
- Administration, Oral
- Colitis, Ulcerative -- diagnosis
- Cost-Benefit Analysis
- Drug Administration Schedule
- Gastrointestinal Agents -- administration & dosage
- Humans
- Mesalamine -- administration & dosage
- Netherlands
- Patient Compliance
- Quality-Adjusted Life Years
- Randomized Controlled Trials as Topic
- Remission Induction
- Research Design
- Severity of Illness Index
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.